NRAS and acute myeloid leukemia: We found significantly higher prevalence proportions of FLT3 (p < 0.001), NPM1 (p < 0.001), WT1 (p < 0.001), CEBPA (p < 0.001), GATA2 (p < 0.001), PTPN11 (p = 0.01), and TET2 (p = 0.006) mutants in NK-AML compared with AK-AML, whereas mutated NRAS (p = 0.05), KIT (p < 0.001), and KRAS (p < 0.001) were more rarely detected in NK-AML.